Stocx Research Club logo ×
Screener Research Unlisted Startup Funding

Aditya Sharma    

Mumbai, India

I am a MBA students and simultaneously reading on capital market to get some knowledge on fundamental research where I more focus on business model, opportunity size of the industry and their related parameters who help me out to find out great businesses for the investment. Nevertheless, I always look forward to learn about grow further into the same.

Read More..
Contributor since: 2022







Syngene International Ltd

Syngene International Ltd.: Q2FY23 Result Update

About The Company

Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.

Q2FY23 Operating Highlights

  • Positive performance across all divisions
  • Sustained growth in research divisions - Discovery Services, including Synvent, our integrated drug discovery platform - and the Dedicated Centres
  • Growth in Development Services led by existing clients renewing contracts and setting up collaborations on additional projects
  • Successfully completed the process performance qualification batches at a commercial scale for Zoetis
  • On track for the regulatory audits, which will pave the way for the commercial manufacturing of the drug substance for Librela®*, a Zoetis product, from the fourth quarter of FY23
  • Continued to invest in new infrastructure and capability-building

Key Facts and Figure

Business Segments

Research Business

Discovery Services

Flexible Platform with capability across multiple modalities including small molecule, large molecule,  peptides, oligonucleotides, antibody
drug conjugates, PROTACs

SynVent our proprietary platform for Integrated Drug Discovery

Dedicated R&D Centers

Ring-fenced infrastructure for exclusive operations for an individual client

Dedicated, multi-disciplinary team of scientists Access to entire Syngene ecosystem

for specialist research and development operations

Development and Manufacturing Business

Development Services

Pre-clinical to clinical trials

Drug substance and drug product development

Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate

cGMP-compliant manufacturing of clinical supplies, and registration batches for small molecules

Manufacturing Services

Manufacturing of small and large molecules for commercial supplies

cGMP-compliant facilities

State-of-the art API manufacturing and biologics manufacturing facilities

Capex Update

Financial Performance

Q2FY23 Financial Snapshot






I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Business relationship disclosure:

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Stocx Research Club). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure:

Source - Company's quarterly announcements, Concall and Presentation. Disc - Given company in the article is not for an recommendation.

Disclosure legality:

I am not a SEBI Registered individual/entity and the above research article is only for educational purpose and is never intended as trading/investment advice.


Updated : Mar, 2023

Updated : Mar, 2023

Equity Research Report: Reliance Industries Ltd (RIL...

RIL may scale 2866 by June’23, 3392 by Mar’24, 4017-4758 by Mar’25 amid expected robust O2C, retail, telecom/digital and Oil & gas (E&P) business


Updated : Mar, 2023

Updated : Mar, 2023

Jubiliant Foodworks Limited

HSBC Webinar with Jubiliant Foodworks Management Meet Note

Author : Krishan Varma

Updated : Mar, 2023

Electronics Mart India Ltd

A Business Analysis

Author : Krishan Varma

Updated : Mar, 2023

Ami Organics Ltd

A Business Analysis

Author : Meghna Rathod

Updated : Jun, 2022

Equity Research Report: Sakar Healthcare

Sakar Healthcare Ltd is engaged in manufacturing of pharmaceutical formulations in the form of liquid injectables, tablets/ capsules, oral liquid syrups, dry powder injectables and syrups. Presently, its domestic sales accounts for 31% of revenues and ...

Author : Akshita

Updated : Jun, 2022


Newgen Software Technologies is a global software Company and is engaged in the business of software product development including designing and delivering end-to-end software solutions covering the entire spectrum of software services from workflow au...

Author : Akshita

Updated : Jun, 2022

Nifty and Bank Nifty Tumbles Due to Weak Global Cues...

Nifty and Bank Nifty tumbles due to weak global cues lead by higher inflation data, higher crude oil prices and weakening currency.

Author : Shalom Martin

Updated : Jun, 2022

Equity Research Report: Shree Renuka Sugar

Shree Renuka Sugars is a global agribusiness and bio-energy corporation. The Company is one of the largest sugar producers in the world, the leading manufacturer of sugar in India, and one of the largest sugar refineries in the world.

Author : Akshita

Updated : Jul, 2022

Equity Research : Tata Consumer Products Limited

TCPL future ambitions remain aggressive, At 17% EPS CAGR over FY22-25e, TCPL should deliver industry-leading growth within indian FMCG.

Author : Shalom Martin

Updated : Jul, 2022

Equity Research: Birlasoft Ltd

Birlasoft, a small-cap IT company, has an upside potential of 35%. The company’s repeated demonstration of ‘walking the talk’ makes us believe that it is on track to achieve its stated target of USD1bn revenue by FY25E.

Author : Shalom Martin